Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021




Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

Focus on SER-287 and SER-301, Seres’ microbiome therapeutic candidates in development for ulcerative colitis

Event to be held ahead of Phase 2b ECO-RESET study clinical induction results anticipated in mid-2021, with additional microbiome pharmacology data expected in H2 2021

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis (UC) on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET.

During the event, Seres’ management and Stephen Hanauer, M.D., Professor of Medicine at Northwestern University Feinberg School of Medicine will discuss the UC patient burden, the need for new therapeutic approaches, and SER-287 and SER-301, Seres’ microbiome therapeutic candidates in clinical development for UC.

Seres is conducting a Phase 2b trial of SER-287 in individuals with active mild-to-moderate UC. SER-287 is an oral microbiome therapeutic candidate designed to restructure the gastrointestinal microbiome and reduce inflammation. Topline clinical data from the SER-287 Phase 2b induction study are expected in mid-2021 and additional microbiome pharmacology data are expected in H2 2021. Seres is also evaluating SER-301, a cultivated rationally designed microbiome therapeutic candidate, in a Phase 1b study in individuals with active mild-to-moderate UC.

To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com. To access the event via conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5387033.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track Designation and Orphan Drug Designation for the treatment of pediatric UC from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit www.serestherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the potential of microbiome therapeutics to treat and prevent disease, the timing and results of our clinical studies, the potential approval of any of our products, and other statements which are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the impact of the COVID-19 pandemic; our unproven approach to therapeutic intervention; the lengthy, expensive and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize our product candidates, if approved; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 4, 2021, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts

PR Contact
Kristin Ainsworth

kainsworth@serestherapeutics.com

IR Contact
Carlo Tanzi, Ph.D.

ctanzi@serestherapeutics.com